health

A company called Cellular Intelligence has acquired global rights to STEM-PD, a stem cell therapy for Parkinson's being developed from human embryonic stem cells. The therapy works by growing dopamine-producing nerve cells in the lab and transplanting them directly into the brain, with the goal of physically replacing the neurons that Parkinson's destroys — something no current medication can do. This is a business deal (a press release, not new clinical data), but it carries real significance for the program's future: Novo Nordisk, the pharmaceutical giant that previously held the rights, is staying on as an equity investor, and the FDA has granted the program Fast Track designation (a status that can speed up regulatory review) and cleared it to advance into Phase 2.

The science behind the therapy is promising but still early. In rat models of Parkinson's, STEM-PD cells survived transplantation, matured into working dopamine neurons, connected to the right brain regions, and reversed motor deficits — with no tumour formation observed up to nine months post-transplant. A first-in-human Phase 1/2 trial (NCT05635409) enrolled eight participants at sites in the UK and Sweden. The first four patients showed positive early safety signals, allowing the trial to move to a higher dose group. Full safety, tolerability, and cell survival data are being tracked for up to three years.

For people living with Parkinson's, this is cautiously hopeful news on a longer horizon. The deal brings an AI-focused company with manufacturing expertise into a program that had solid academic and pharma backing — potentially accelerating development and reducing cost. That said, this is still a tiny Phase 1/2 safety trial in eight people; no efficacy data have been published yet. It targets adults aged 50–75 with moderate Parkinson's (more than 10 years into the disease, symptoms not well controlled by oral medications). If you fit that profile, it may be worth asking your neurologist about the trial or watching for Phase 2 recruitment. Realistically, even if Phase 2 succeeds, a widely available cell therapy is still many years away.